BD (Becton, Dickinson and Company), a medical technology company, has announced a partnership with the US government under which the company has agreed to invest $19 billion in the US over several years, including capital, operational, and supply-chain investments, while gaining certain relief from tariffs, when finalized, under Section 232 of the Trade Expansion Act of 1962, which include sector-specific tariffs.  

BD is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products, which include syringes, needles, infusion pumps, and other medical products. 

Of the $19-billion commitment, $3 billion is allocated toward US manufacturing expansion focused on what the company says are strategic production sites across the country. The investment will expand end-to-end U.S. production by approximately 5 billion essential medical consumables annually, raising BD’s share of domestically supplied essential medical consumables to roughly 80%. The company also has agreed to manufacture 100% of BD needles used in the US domestically using American-made steel. 

BD’s manufacturing network in the US includes sites in the following locations: Columbus and Broken Bow, Nebraska; Canaan, Connecticut; Añasco, Puerto Rico; Sandy, Utah; El Paso, Texas; Covington, Georgia; and Sumter, South Carolina. 

The agreement also provides relief from future tariffs imposed under Section 232 on covered BD products and inputs, subject to the final scope and implementation of any future Section 232 actions and BD’s achievement of agreed milestones. The company says that because the final tariff rates, product scope and effective timing have not yet been determined, BD is not currently quantifying the financial impact of the agreement. The company expects to provide additional information when the Section 232 tariffs are finalized.    

Source: BD